Rui Zou
Suzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Epigenetic priming with azacitidine-BEAM versus decitabine-BEAM conditioning for autologous transplantation in non-Hodgkin's lymphoma.
Journal: Bone marrow transplantation
Published: April 26, 2026
Long-Term Follow-Up of Chidamide With Chemotherapy in Untreated Peripheral T-Cell Lymphoma: One Single Center Real-World Study in China.
Journal: Hematological oncology
Published: October 03, 2025
A facile and sensitive protein immune polyacrylamide gel electrophoresis with online fluorescent imaging.
Journal: Analytica chimica acta
Published: June 05, 2025
Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma.
Journal: Cancer immunology, immunotherapy : CII
Published: June 01, 2025
Influence of the gut microbiome on lymphoma treatment: current evidence and future therapeutic directions.
Journal: Therapeutic advances in medical oncology
Published: March 30, 2025
Case report: CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B-related cirrhosis.
Journal: Frontiers in oncology
Published: September 04, 2024
Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed/refractory non-Hodgkin lymphoma: Current studies and future prospects.
Journal: Critical reviews in oncology/hematology
Published: September 27, 2023
Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review.
Journal: Frontiers in oncology
Published: August 25, 2023
Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center.
Journal: Frontiers in immunology
Published: April 05, 2023
Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient.
Journal: Cancer research and treatment
Published: February 08, 2023
Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
Journal: Frontiers in immunology
Published: June 15, 2022
Showing 1-11 of 11
Last Updated: 09/26/2026